SOUTH EASTON, Mass., Nov. 2, 2012 - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that scientists from two separate research groups presented data at the recent HUPO 11th Annual World Congress (Boston, MA) indicating that the incorporation of the Company's Pressure Cycling Technology ("PCT") Platform into their sample preparation processes resulted in a marked improvement in the quality and/or efficiency of test results. These studies were presented by scientists from the Center for Biologics Evaluation and Research of the Food and Drug Administration ("FDA") and from Janssen Research and Development ("Janssen").
Dr. Michail Alterman and colleagues from the FDA presented on the "Global Proteomic Architecture of Culture-Expanded Human Bone Marrow Multipotent Stromal Cells (MSCs) and the Proteomic Basis of Heterogeneity". MSCs are believed to offer huge potential for cell-based therapies for a wide variety of diseases. Currently, MSC studies are primarily focused on highly abundant proteins, which are generally unable to reveal important cellular events. The authors presented on the use of a highly improved approach to sample preparation and protein identification. This approach allowed them to better identify and analyze events likely to control the biology of the MSCs. Such information could be essential in the design and development of new, life-saving cell-based therapies. The authors reported that PCT was an important part of their improved sample preparation approach.
Scientists from Janssen Research & Development (a Johnson & Johnson Company) presented on the "Evaluation of Pressure-Assisted Enzymatic Digestion for the Optimal Digestion of Monoclonal Antibodies". Monoclonal antibodies are widely used in scientific research, in diagnostics, and in therapeutics. However, it is essential that monoclonal antibodies be thoroughly identified and characterized before use. This process most often requires the use of an enzyme to completely digest the monoclonal antibody into its basic building blocks. The digestion process can be time-consuming, requiring as long as 24 hours to complete. The authors reported that "pressure-assisted enzymatic digestion" (e.g., PCT) was very effective in significantly reducing the total time required to digest monoclonal proteins and to expedite their complete characterization.
Dr. Nate Lawrence, Vice President of Sales and Marketing for PBI, commented: "We are very pleased that two highly respected scientific teams have shown that the incorporation of the PCT Platform in their sample preparation workflow resulted in significant advantages, including savings in analysis time and improvements in test and result quality. Cell-based therapies are believed to offer enormous potential for improving human healthcare and the quality of life. The monoclonal antibody market is believed to be in the tens of billions of dollars. Consequently, we believe that the results presented by FDA and Janssen scientists at HUPO 2012 bode well for an increased demand of our PCT Platform in 2013 and beyond."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the marked improvement in MSC test results and enzymatic digestion using PCT; that MSCs offer huge potential for cell-based therapies; that highly abundant proteins do not reveal important cellular events; that the improved FDA approach allows better identification and analysis of MSC events, which could lead to new, life saving cell-based therapies; that monoclonal antibodies are widely used in scientific research, diagnostics, and therapeutics; that pressure-assisted enzymatic digestion effectively reduces digestion time and complete characterization of monoclonal antibodies; that cell-based therapies offer enormous potential for improving human healthcare and quality of life; that the monoclonal antibody market is believed to be in the tens of billions of dollars; and that the results presented by the FDA and Janssen scientists bode well for an increased demand of the PCT Platform in 2013 and beyond. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond December 2012. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond December 2012 on acceptable terms, if at all. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
PBI filed a registration statement (including a prospectus) with the SEC for an offering to which this communication may relate. Before you invest, you should read the prospectus in that registration statement for the offering and other documents PBI has filed with the SEC for more complete information about PBI and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, PBI can arrange to send you the prospectus, when available, upon request.
For more information about PBI and this press release, please click on the following link:
Richard T. Schumacher
President & CEO
Pressure BioSciences, Inc.
Vice President of Sales & Marketing
(508) 230-1828 (T)
SOURCE Pressure BioSciences, Inc.